Abstract

Aim
To report the long-term local control and survival of patients with early breast cancer who had hypofractionated whole breast irradiation with concomitant boost (Hypo-CB).

Methods and materials
Between October 2009 and June 2010, 73 patients with early breast cancer (T1-3N0-1M0) who underwent breast conserving surgery were enrolled into the study. Thirty-six of these participants received 50 Gy of conventional irradiation in 25 fractions over 5 weeks to the whole breast with a sequential boost to the tumor bed with 10–16 Gy in 5–8 fractions (Conv-SEQ). The other 37 participants received a hypofractionated dose of 43.2 Gy in 16 fractions with an additional daily concomitant boost (CB) of 0.6 Gy over 3 weeks (Hypo-CB).

Results
At a median follow-up time of 123 months, ipsilateral local recurrence (ILR) was found in 3 participants, 1 of whom was in the hypofractionated group. All 3 ILR were true local recurrence (TR). There were no significant differences in the 10-year disease free survival (DFS) and 10-year overall survival rates (OS) between the conventional and hypofractionated groups (93.9% vs. 94.4%, p = 0.96 and 91.9% vs. 91.6%, p = 0.792, respectively).

Conclusion
This study showed that the effectiveness, DFS and OS were comparable between hypofractionated whole breast irradiation with a CB and the conventional irradiation with a sequential boost.
Introduction
After breast conserving surgery, followed by an adjuvant whole breast radiation treatment is the standard of care for early breast cancer. A number of phase III randomized studies have confirmed the benefits of adjuvant radiation in terms of reduction in the local recurrence and improved breast cancer specific survival [1–6]. The Early Breast Cancer Trialists’ Collaborative Group meta-analysis revealed that adjuvant radiation reduced the 10-year risk of locoregional and distant recurrences by approximately 15%, while it reduced the 15-year risk of breast cancer death by approximately 4% [7]. The conventional radiation to the whole breast is 45–50 Gy, administered in 1.8–2 Gy per fraction doses over 5–6 weeks [1, 8].

Four pivotal randomized studies reported no significant differences in local control, toxicity and cosmesis between hypofractionated and conventional fractionation, hence, hypofractionation is now the most common treatment for patients with early breast cancer [9–15].

The effect of a tumor bed boost has been shown to improve local control rates. Bartelink et al. reported an absolute 4% lower 20-year cumulative incidence of ipsilateral breast cancer recurrence when a tumor bed boost is administered, but the incidence of skin fibrosis was higher in the tumor bed boost treated group [16, 17]. In another study, Lyon et al. showed consistent results that treatment with a tumor bed boost provided ipsilateral breast tumor control without much impact on toxicity [18].

Conventionally, a sequential tumor bed boost would be added to the whole breast irradiation which prolonged the overall treatment duration. In the START A trial, a 13 fraction regimen was used for 5 weeks, while the START B trial used a 15 fraction regimen for 3 weeks. Approximately 60% of the patients in START A and 40% from START B trials received a tumor bed boost, delivered in 5 sequential conventional fractions of 10 Gy. Both studies reported no increase in adverse events from tumor bed boost.

Simultaneous or concomitant boost for breast cancer has been adopted by many cancer institutes because the treatment duration is shorter and a higher dose is administered to the tumor bed which is the most frequent site of recurrence [19–21]. The toxicity and the cosmetic outcome are both acceptable. This technique administers whole breast irradiation and boost concomitantly. Recently, Krug et al. has published the data affirming that the toxicity is low and treatment compliance is high [22].

However, there is limited data on the long-term effects of hypofractionated CB treatment. At most, there is data up to 5 years post treatment. Thus, in this study, we report the 10-year follow-up of the efficacy of hypofractionated CB treatment.

Materials and methods
Study population
Between 2009 and 2010, a total of 73 patients with operable invasive breast cancer (T1-3N0-1M0) who had undergone breast conserving surgery were enrolled into the study. Thirty-six of these participants received conventional radiation (Conv-SEQ) and 37 participants received hypofractionated radiation (Hypo-CB). Both radiotherapy fractionation schemes are standard of care in our hospital. The treatment schedule was assigned by the radiation oncologists. Patients with T1-3N0-1M0, aged 18 or older and had resected tumor margins wider than 1 mm were enrolled into the study. We incorporated a boost to the tumor bed in this study (0.6 Gy for 16 fractions), by delivering a biologically effective dose (BED) of 96.36 Gy (with an α/β value of 4 Gy) which is equivalent to the sequential regimen of BED 90 Gy. The adjuvant systemic treatment was administered according to the NCCN Clinical Practice Guidelines in Oncology [23]. Patients with prior radiation to the thoracic area, patients with bilateral breast
cancer, patients with breast carcinoma with skin involvement, patients with connective tissue
disease and patients requiring concurrent chemoradiation were excluded from the study. The
study protocol was approved by the Research Ethics Committee of King Chulalongkorn
Memorial Hospital and written informed consent was obtained from all patients. Patients who
deprecated to take part in the study received the same standard of care as the patients who agreed
to take part in the study.

Definitions
Ipsilateral local recurrence (ILR) was defined as an in situ/invasive carcinoma that recurred
after breast conserving therapy in the ipsilateral breast with or without regional recurrence or
distant metastases. True local recurrence (TR) was defined as an invasive carcinoma that
occurred in the same area/quadrant of the prior tumor bed and required tissue biopsy for
pathological confirmation. Disease free survival (DFS) was defined as the time duration after
radiotherapy during which no disease had been found. Overall survival rate (OS) was defined
as the time after breast conserving therapy to death from any cause.

Radiotherapy
The participants either received 50 Gy in 25 fractions followed by a sequential 10–16 Gy boost
to the tumor bed or 43.2 Gy in 16 fractions with a concurrent boost of 0.6 Gy for each fraction.
Radiation was administered over 5 and 3 weeks for the conventional and hypofractionated
groups, respectively. The details of the radiation technique have been previously described
[24]. Briefly, all of the participants were treated in the supine position on a breast board with
arms above the head. Whole breast irradiation was performed either using two-dimensional
(2D) radiation technique with two 6–10 MV tangential fields, with or without wedges, or
three-dimensional (3D) conformal technique. An en-face electron beam was used for tumor
bed boost, prescribed at 90% isodose line. Eclipse TPS version 7.3.10 was used to calculate the
distribution of the radiation dose. The VARIAN Linear Accelerators machines were used to
treat all of the participants (The Varian 21EX, 23EX, RapidArc, Clinac iX or TRUEBEAM
accelerators). An Electronic Portal Imaging Device was used to perform a set-up verification
prior to the delivery of each radiotherapy daily fraction. Fig 1 depicts an example of treatment
planning.

Statistical analysis
Baseline characteristics were described as percentages for categorical data and as mean (SD)
for continuous data. Data were compared using Chi-square tests for categorical variables and
Student’s t-tests for continuous variables. Disease free survival and overall survival were calcu-
lated using the Kaplan–Meier method. Log rank test was used to compare survival between 2
groups. All tests were two-sided and P values of less than 0.05 was considered statistically sig-
nificant. All analyses were performed using IBM SPSS statistics (Version 22.0).

Follow up
The participants were followed every 3–4 months for the first few years and 6 months for year
4 and 5, and then yearly after that. They were seen by surgeons, medical oncologists and radia-
tion oncologists in separate clinics. At each follow-up, medical history was collected, physical
examination was performed, and toxicity was assessed. Mammogram and breast ultrasound
were performed 6 months after radiation therapy and then yearly. The late toxicity outcome
was assessed by the RTOG/EORTC late radiation morbidity scoring scheme [25].
Results

The median follow-up time was 123 months (range 21–135 months). Totally, 73 participants were enrolled into the study. Thirty-six participants were in Conv-SEQ group and 37 participants were in Hypo-CB group. One participant was lost to follow-up. The baseline characteristics are summarized in Table 1 and are comparable between the 2 study groups. The median age was 52 years (range, 33–76 years) and 47.1% of the participants were T1 and 84.9% were N0. Eighty nine percent of the participants had Invasive ductal carcinoma and 80.2% of the participants had a negative resected margin (>1 mm width). Seventy-one percent of the participants were ER positive, 24.7% were ER negative, 20.5% were HER2 positive and 64.4% were HER2 negative. Sixty-eight percent of the participants received 2D radiation technique, and 31.5% were treated with 3D radiation technique. Participants who had chemotherapy received 1 of the following regimens: CMF (cyclophosphamide, methotrexate and 5-fluorouracil), AC (doxorubicin and cyclophosphamide) and/or taxane regimen, starting 3–4 weeks after surgery.

Outcomes

The ipsilateral local recurrence (ILR) was found in 3 participants of which 2 were from the Conv-SEQ group. Two of the participants had invasive cancers, and 1 had a ductal carcinoma in situ. The clinico-pathologic and treatment details of the 3 recurrences are listed in Table 2. All 3 recurrences were eligible for salvage surgery, either wide excision or mastectomy. At the time of analysis, 82.2% of the participants were alive without disease recurrence. There were 3 participants who had regional and distant metastases and 1 participant developed distant metastases without locoregional recurrence. At 10 years, DFS rate was not significantly different between Hypo-CB and Conv-SEQ (94.4% and 93.9% (p = 0.96), respectively. During this study period, 5 of the participants (6.8%) died. Of these 5 participants, 3 died of breast cancer, and 2 of them were from the hypofractionated group. The other 2 participants died from unknown cause. The 10-year overall survival rate was not significantly different between the 2 groups which had a 10-year overall survival rate of 91.9% for the Hypo-CB group and 91.6% for the Conv-SEQ group (p = 0.792) (Fig 2). Sixty-five (89%) participants had late toxicity. At the time of analysis, there were 5 (7.7%), 56 (86.2%) and 4 (6.2%) participants who had grade...
Table 1. Baseline characteristics by fractionation schedule.

| Characteristics          | No. of participants in the conventional group | No. of participants in the hypofractionated group | p-value |
|--------------------------|---------------------------------------------|--------------------------------------------------|--------|
|                          | N = 36                                      | N = 37                                          |        |
| Age:                     |                                             |                                                 | 0.84   |
| 18–40                    | 5 (13.9%)                                   | 8 (21.6%)                                       |        |
| 41–50                    | 10 (27.8%)                                  | 9 (24.3%)                                       |        |
| 51–60                    | 15 (41.6%)                                  | 15 (40.5%)                                      |        |
| > 60                     | 6 (16.7%)                                   | 5 (13.6%)                                       |        |
| Mean (SD)                | 50 (10.4)                                   | 49.8 (9.5)                                      |        |
| Stage:                   |                                             |                                                 | 0.73   |
| 0 (Tis)                  | 4 (11.1%)                                   | 3 (8.1%)                                        |        |
| I                        | 13 (36.1%)                                  | 15 (40.5%)                                      |        |
| IIA                      | 19 (52.8%)                                  | 18 (48.7%)                                      |        |
| IIB                      | 0 (0%)                                      | 1 (2.7%)                                        |        |
| Histology:               |                                             |                                                 | 0.99   |
| IDC                      | 31 (86.2%)                                  | 32 (86.5%)                                      |        |
| ILC                      | -                                           | -                                               |        |
| DCIS                     | 4 (11.1%)                                   | 4 (10.8%)                                       |        |
| other                    | 1 (2.7%)                                     | 1 (2.7%)                                        |        |
| Margin:                  |                                             |                                                 | 0.36   |
| < 1 mm                   | 8 (22.3%)                                   | 6 (16.2%)                                       |        |
| ≥ 1 mm                   | 28 (77.7%)                                  | 31 (83.8%)                                      |        |
| Tumor grade:             |                                             |                                                 | 0.96   |
| Grade I                  | 6 (16.7%)                                   | 7 (18.9%)                                       |        |
| Grade II                 | 10 (27.8%)                                  | 10 (27.1%)                                      |        |
| Grade III                | 14 (38.9%)                                  | 16 (43.2%)                                      |        |
| Unknown                  | 6 (16.6%)                                   | 4 (10.8%)                                       |        |
| Lymphovascular invasion  |                                             |                                                 | 0.67   |
| Absent                   | 12 (33.3%)                                  | 16 (43.2%)                                      |        |
| Present                  | 3 (8.3%)                                     | 3 (8.1%)                                        |        |
| Unknown                  | 21 (58.4%)                                  | 18 (48.7%)                                      |        |
| Ki 67 level              |                                             |                                                 | 0.60   |
| <14                      | 10 (27.8%)                                  | 14 (37.8%)                                      |        |
| ≥15                      | 19 (52.8%)                                  | 18 (48.6%)                                      |        |
| Unknown                  | 7 (19.4%)                                   | 5 (13.6%)                                       |        |
| Tumor subtype:           |                                             |                                                 | 0.48   |
| ER +/- HER2-             | 18 (50%)                                     | 20 (54.1%)                                      |        |
| ER +/HER2+               | 6 (16.7%)                                   | 5 (13.5%)                                       |        |
| ER-/HER2-                | 6 (16.7%)                                   | 3 (8.1%)                                        |        |
| ER-/HER2+                | 3 (8.3%)                                     | 1 (2.7%)                                        |        |
| ER+/HER2 unknown         | 2 (5.6%)                                     | 6 (16.2%)                                       |        |
| unknown                  | 1 (2.7%)                                     | 2 (5.4%)                                        |        |
| Treatment:               |                                             |                                                 | 0.22   |
| Surgery                  | 0 (0%)                                       | 2 (5.4%)                                        |        |
| Surgery and chemotherapy | 9 (25%)                                      | 6 (16.2%)                                       |        |
| Surgery and hormonal treatment | 14 (38.9%)   | 10 (27%)                                        |        |
| Surgery, chemotherapy and hormonal treatment | 13 (36.1%) | 19 (51.4%)                                      |        |
| Radiation technique:     |                                             |                                                 | 0.57   |
| 2D                       | 24 (66.6%)                                  | 27 (73%)                                        |        |

(Continued)
0.1, 2 skin toxicities, respectively. There was no statistical difference in late toxicity between the 2 groups (p = 0.072).

**Discussion**

Multiple randomized phase III studies have confirmed that local control rates for breast cancer increase when boost to the tumor bed in conventional fractionation is used [16–18, 26–29]. A Cochrane systematic review assessed 5 randomized controlled trials of patients with or without boost treatment revealed that local control was significantly better for patients receiving a tumor bed boost compared to patients who did not have a tumor bed boost (HR 0.64, 95% CI 0.55–0.75). However, there were no differences in terms of disease free survival and overall survival between the tumor bed boost and no boost groups (HR 0.94, 95% CI 0.87–1.02 and HR 1.04, 95% CI 0.94–1.14, respectively) [30].

Incorporating a CB to the tumor bed in this study increase the radiation dose to the tumor bed and shortened the overall treatment duration. Regarding the effectiveness data of hypofraction with concomitant or simultaneous boost, Formenti et al. [31] enrolled patients to receive 40.5 Gy with 0.5 Gy delivered concomitantly to the tumor bed. There was no local recurrence except 1 patient who had regional recurrence at 1-year of follow-up. Morganti et al. [32] evaluated 2 clinical studies of which 1 of those patients received 44 Gy in 16 fractions to the whole breast and 0.25 Gy concomitant boost. There was no local relapse at median follow-up at 31 months. Corvo et al. [33] used the hypofractionated regimen of 46 Gy in 20 fractions to the whole breast, 4 times a week with a concomitant weekly boost of 1.2 Gy. The authors reported no local recurrent at the median follow up at 33 months. Freedman et al. [20]

---

### Table 1. (Continued)

| Characteristics | No. of participants in the conventional group | No. of participants in the hypofractionated group | p-value |
|-----------------|---------------------------------------------|-----------------------------------------------|---------|
|                 | N = 36                                      | N = 37                                        |         |
| 3D              | 12 (33.3%)                                  | 10 (27%)                                      | 0.30    |
| **Boost**       |                                             |                                               |         |
| Yes             | 35 (97.2%)                                  | 37 (100%)                                     |         |
| No              | 1 (2.8%)                                    | 0 (0%)                                        |         |

Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, Estrogen receptor; HER2, human epidermal growth factor receptor 2; 2D, two-dimensional; 3D, three-dimensional.

https://doi.org/10.1371/journal.pone.0258186.t001

### Table 2. Characteristics of the three participants who developed ipsilateral local recurrence.

| Participant ID number | Stage Radiation treatment | Systemic treatment | Time to recurrence (month) | Pathology of recurrence |
|-----------------------|----------------------------|--------------------|----------------------------|-------------------------|
| 34                    | pT2N1M0                    | 60Gy/30Fx          | AC x 4 > T x12 with Trastuzumab | IDC, ER, PR, HER2 3+    |
|                       | ER, PR, DISH+              |                    |                            |                         |
| 35                    | pT1N0M0                    | 52.8Gy/16Fx        | CMFx6                      | IDC, ER90%, PR90%, HER2 2+ |
|                       | Not available IHC          |                    |                            |                         |
| 63                    | pT1N0M0                    | 60Gy/30Fx          | CMFx 6, Tam                |                         |
|                       | ER30%, PR, HER2 2+         |                    | 102                        |                         |

Abbreviations: DISH: Dual in situ hybridization; AC, doxorubicin and cyclophosphamide; T, paclitaxel; CMF, cyclophosphamide, methotrexate and 5 fluorouracil; Tam, tamoxifen.

https://doi.org/10.1371/journal.pone.0258186.t002
reported a 5-year actual rate of local recurrence of 2.7%. In Cante’s study [34], 375 patients received 45Gy of the whole breast irradiation with additional 0.25 Gy for concomitant boost. At approximately 5 years of follow-up, there was no local recurrence, and the 5-year DFS and OS were 96.6 and 97.6%, respectively. In Chadha’s study [21], 160 early breast cancer patients received 40.5Gy (2.7 Gy per fraction) with a concomitant boost of 0.3 Gy in each fraction. At median follow-up time of 3.5 years, the 5-year OS, DFS and local relapse-free survival were 90%, 97% and 99%, respectively. Other ongoing studies such as RTOG 1005 and HYPOSIB have not yet reported their results [35, 36]. As for our study, the 10-year actual rate of ILR was 4.1% which was quite low. The results were consistent to the aforementioned studies and the 6 pivotal trials.

Several studies have shown that breast cancer cells have lower levels of α/β, and that with an increased BED with SIB technique could improve local tumor control. However, this technique can increase late toxicity which is of concern. Our data revealed that there was no significant late toxicity when the SIB technique was used compared to the conventional scheme. The IMPORT HIGH trial recently published a 3-year adverse effects of 2,617 breast cancer patients. The authors assessed the dose escalation using SIB or sequential boost after breast conservation surgery. At median follow-up time of 4 year, the rates of moderate and high-grade adverse effects were similar among all treatment groups. There was slight increase in breast induration in the hypofractionated SIB treatment group (53 Gy/15Fx to tumor bed) [37, 38]. The HYPOSIB reported that there was no grade3-4 skin toxicity and the cosmetic outcome was good to excellent at 3 years follow-up [36]. Our results were similar to other studies.
as there were no severe toxicity and most of the participants experienced grade 0–1 skin toxicity.

There are some limitations in our study. First, this is not a randomized study and the assignment of the treatment depended on the radiation oncologists. However, the baseline characteristics of both groups were comparable. Second, 69% of our participants received electron tumor bed boost which might result in dose inhomogeneity and non-conformity. Third, we use the surgical scar, the seroma or the distorted tissue plane in case with cavity closure to visualized the CT planning for tumor bed localization. This method was not as precise as the clip-based localization technique.

In terms of the radiation techniques, 60–70% of our participants were treated with conventional technique. Donovan et al. [39] compared between 3D intensity modulated radiotherapy and 2D treatment planning. Although, breast appearance was statistically significantly higher in the 2D treatment arm but there were no significant differences in the patients’ quality of life. However, the key strength of the present study was the high rate of study completion (98.6%). As far as we know, this study is the first to evaluate the long-term efficacy of hypofraction with CB. The follow-up period of this study was 10 years post surgery.

In the light of COVID-19 pandemic situation, this radiation protocol may be deemed more appropriate for the patients because there are fewer clinic visits, thus limiting the exposure to COVID-19.

Conclusion

Our long-term follow up results showed that the incorporation of a tumor bed boost concomitantly with hypofractionated whole breast irradiation is an effective treatment with low local recurrence rate, excellent DFS and OS.

Acknowledgments

We would like to acknowledge the support of the Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Author Contributions

Conceptualization: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Data curation: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Formal analysis: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Investigation: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Methodology: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Project administration: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Resources: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Software: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Supervision: Prayuth Rojpornpradit.
Validation: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Visualization: Kitwadee Saksornchai, Prayuth Rojpornpradit.
Writing – original draft: Kitwadee Saksornchai, Prayuth Rojpornpradit.
References

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17; 347:1239–41. https://doi.org/10.1056/NEJMoa021529 PMID: 12393820

2. Arriagada R, Le MG, Guinebretière JM, Dunant A, Rochard F, Turaz T. Late local recurrences in a randomised trial comparing conservative surgery with total mastectomy in early breast cancer patients. Ann Oncol. 2003 Nov 1; 14:1617–22. https://doi.org/10.1093/annonc/mdg452 PMID: 14581268

3. Blichert-Toft M, Nielsen M, Düring M, Møller S, Rønkaold M, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother and Oncol. 2005 Oct 1; 79:331–41. https://doi.org/10.1016/j.radonc.2005.01.005 PMID: 15878095

4. Brunt AM, Haviland JS, Syedhnam M, Agrawal RK, Algorafi H, Alhaas A, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020 Oct 1; 38:3261–3272. https://doi.org/10.1200/JCO.19.02750 PMID: 32663119

5. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer.
17. Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015 Jan 1; 16:47–56. https://doi.org/10.1016/S1470-2045(14)71156-8 PMID: 25500422

18. Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet JM, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997 Mar; 15:963–8. https://doi.org/10.1200/JCO.1997.15.3.963 PMID: 9060534

19. Bantema-Joppe EJ, Schlister C, de Bock GH, Dolsma WV, Busz DM, Langendijk JA, et al. Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months’ follow-up. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83:e471–7. https://doi.org/10.1016/j.ijrobp.2012.01.050 PMID: 22494592

20. Freedman GM, Anderson PR, Bleicher RJ, Litwin S, Li T, Swaby RF, et al. Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84:888–93. https://doi.org/10.1016/j.ijrobp.2012.01.091 PMID: 22580118

21. Chadha M, Vongtama D, Friedmann P, Parris C, Boolbol SK, Woode R, et al. Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin breast cancer. 2012 Feb 7; 12:57–62. https://doi.org/10.1016/j.clbc.2011.09.002 PMID: 22056970

22. Krug D, Baumann R, Krockenberger K, Vonthein R, Schreiber A, Boicev A, et al. Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial. Strahlenther Onkol. 2021 Jan; 197:48–55. https://doi.org/10.1007/s00066-020-01689-7 PMID: 33001241

23. National Comprehensive Cancer Network. (2006). Breast cancer (version 1.2006). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

24. Saksornchai K, Rojpornpradit P, Shotelersak K, Chakkabat C, Raiyawat P. Skin toxicity and cosmesis after hypofractionated whole breast irradiation for early breast cancer. J Med Assoc Thai. 2012 Aug 3; 95:229. PMID: 22435254

25. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31:1341–6. https://doi.org/10.1016/0360-3016(95)00060-C PMID: 7713792

26. Polgár C, Fodor J, Orosz Z, Major T, Takács-Nagy Z, Mangal LC, et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I–II breast cancer. Strahlenther Onkol. 2002 Nov 1; 178:615–23. https://doi.org/10.1007/s00066-002-1053-1 PMID: 12426672

27. Teissier E, Héry M, Ramaioi A, Lagrange JL, Courdi A, Bensadoun RJ, et al. Boost in conservative treatment: 6 years results of randomized trial. Breast Cancer Res Treat. 1998; 50:287.

28. Graham P, Browne L, Capp A, Fox C, Delaney G, Kearsley H, et al. Randomized trial shows reduced whole breast dose negates benefit of lumpectomy radiotherapy boost. Radiother Oncol. 2010; 95:S145.

29. Graham P, Browne L, Capp A, Fox C, Delaney G, Kearsley J, et al. The St George, Wollongong and Liverpool Breast Cancer Trial: 1st planned analysis at 6-year mean follow-up. Australas Radiol. 2007 Oct 1; 51:865.

30. Kindts I, Laenen A, Depuydt T, Welten C. Tumour bed boost radiotherapy after surgery for early breast cancer: the clinical experience at Genoa University. Anticancer Res. 2010 Nov 1; 30:4749–51. PMID: 21159355

31. Corvo R, Ricchetti F, Dinoi D, Torelli P, Agostinelli S, Cavagnotto F, et al. Adjuvant hypofractionated radiotherapy with weekly concomitant boost for women with early breast cancer: the clinical experience at Genoa University. Anticancer Res. 2010 Nov 1; 30:4749–51. PMID: 21159355

32. Fornier SC, Gidea-Addeo D, Goldberg JD, Goldberg JD, Rosenthal BS, et al. Phase-I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol. 2007 Jun 1; 25:2236–42. https://doi.org/10.1200/JCO.2006.09.1041 PMID: 17470849

33. Morganti AG, Cilla S, Valentini V, Macchia G, Deodato F, Ferrandina G, et al. Phase-I-II studies on accelerated IMRT in breast carcinoma: technical comparison and acute toxicity in 332 patients. Radiother Oncol. 2009 Jan 1; 90:86–92. https://doi.org/10.1016/j.radonc.2008.10.017 PMID: 19010560

34. Corvo R, Ricchetti F, Dinoi D, Torelli P, Agostinelli S, Cavagnotto F, et al. Adjuvant hypofractionated radiotherapy with weekly concomitant boost for women with early breast cancer: the clinical experience at Genoa University. Anticancer Res. 2010 Nov 1; 30:4749–51. PMID: 21159355

35. Cante D, Franco P, Sciaccio P, Girelli G, Marra AM, Pasquino M, et al. Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Med Oncol. 2013 Jun 1; 30:518. https://doi.org/10.1007/s12032-013-0518-7 PMID: 23460537
35. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Identifier NCT00287391, Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery; 2011 May 6 [cited 2020 Nov 1]. https://clinicaltrials.gov/ct2/show/NCT01349322?term=RTOG+1005&rank=1

36. Dellas K, Vonthein R, Zimmer J, Dingess S, Boicev AD, Andreas P, et al. ARO Study Group. Hypofractionation with simultaneous integrated boost for early breast cancer. Strahlenther Onkol. 2014 Jul 1; 190:646–53. https://doi.org/10.1007/s00066-014-0658-5 PMID: 24737540

37. Coles C, Yarnold J. IMPORT Trial Management Group. The IMPORT Trials are launched. Clin Oncol. 2006; 18:587e590. https://doi.org/10.1016/j.clon.2006.07.010 PMID: 17051947

38. Chatterjee S, Mahata A, Mandal S, Chakraborty S. Simultaneous integrated boost: improving the patient journey during breast cancer radiotherapy safely. Clin Oncol. 2019 Apr 1; 31:266. https://doi.org/10.1016/j.clon.2018.12.004 PMID: 30600192

39. Donovan E, Bleakley N, DFenholm E, Evans P, Gothard L, Hanson J, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007 Mar 1; 82:254–64. https://doi.org/10.1016/j.radonc.2006.12.008 PMID: 17224195